Showing results (131-140 of 223) with videos related to

Sort By:
Pageof 23
Annals of Neurology|July 29, 2025
Volumetric MRI Comparing Longitudinal Change in MOGAD to NMOSD, MS and Healthy Controls, and Disability AssociationsAmy Kunchok, Moein Amin, Tatchaporn Ongphichetmetha, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 13, 2019
Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MSEdward J Fox, Fred D Lublin, Jerry S Wolinsky, et al.
European Journal of Neurology|June 4, 2025
Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod TrialsSarah Harris, Giancarlo Comi, Bruce A C Cree, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 20, 2021
Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosisDeja R Rose, Ahmad Z Mahadeen, Alise K Carlson, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 10, 2025
Progressive Myelitis in a 63-Year-Old Woman: A Case Report From the National Multiple Sclerosis Society Case Conference ProceedingsKimberly A DiMauro, Morgan E Heber, Jonathan Lee, et al.
Neurology|January 30, 2015
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosisErnst-Wilhelm Radue, Frederik Barkhof, Ludwig Kappos, et al.
Neurology. Education|May 10, 2024
Curriculum Innovations: Virtual Didactics as a Tool for Harmonizing Education About Rare Topics in NeuroimmunologyJohn Peters, Jeffrey A Cohen, John R Corboy, et al.
Annals of Neurology|July 28, 2010
Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosisPeter J Darlington, Marie-Noëlle Boivin, Christel Renoux, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 10, 2023
Clinical Determinants of Longitudinal Disability in LGI-1-IgG Autoimmune EncephalitisAlbert Aboseif, Yadi Li, Moein Amin, et al.
The Lancet. Neurology|February 17, 2016
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trialJeffrey A Cohen, Douglas L Arnold, Giancarlo Comi, et al.
Pageof 23